Special Issue

Role of Next Generation Vaccines in Immunotherapeutics

Message from the Guest Editor

Vaccines have been instrumental in combating diseases, and next-generation vaccines represent a transformative leap forward in preventing infections and advancing immunotherapeutics. Next-generation vaccines encompass nucleic acid vaccines (DNA and RNA), viral vector vaccines, protein subunit vaccines, and recombinant vector vaccines. They offer several advantages over traditional vaccines, such as rapid development, stability, and the ability to elicit specific immune responses. Nucleic acid vaccines, particularly mRNA vaccines, gained global attention during the COVID-19 pandemic for their rapid development and high efficacy. Viral vector and protein subunit vaccines are also being explored for their potential to develop targeted and less reactive vaccines. Next-generation vaccines also show promise in treating chronic diseases, cancers, and autoimmune conditions. They can target specific tumor antigens in cancer immunotherapy and modulate immune responses in autoimmune diseases and allergies. We invite you to contribute a research or review article linking different components of the virus or vaccine to immune responses and clinical or preclinical data.

Guest Editor

Dr. Swayam Prakash
Institute for Immunology, School of Medicine, University of California Irvine, Irvine, CA 92697, USA

Deadline for manuscript submissions

30 September 2026

Vaccines

an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 7.7
Indexed in PubMed

mdpi.com/si/201210

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

mdpi.com/journal/vaccines

Vaccines

an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 7.7
Indexed in PubMed

mdpi.com/journal/vaccines

MDPI

About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers
Department of Health, Cognition and Behavior, University College Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).